FR960299A
(pt)
|
|
1950-04-15 |
|
|
DE279887C
(pt)
|
|
|
|
|
US3830797A
(en)
|
1964-11-05 |
1974-08-20 |
Pennwalt Corp |
Tertiary-aliphatic-alpha-(peracyl)azo compounds
|
US5874424A
(en)
*
|
1995-12-20 |
1999-02-23 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
US3524858A
(en)
*
|
1967-05-18 |
1970-08-18 |
Warner Lambert Pharmaceutical |
1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
|
US3443939A
(en)
|
1967-07-24 |
1969-05-13 |
Polaroid Corp |
Differential mobility of color moiety in color transfer
|
DE1908548A1
(de)
|
1968-02-29 |
1970-11-05 |
Warner Lambert Co |
Chinolinderivate
|
BE757639A
(fr)
|
1969-10-17 |
1971-04-16 |
Roussel Uclaf |
Nouveaux derives de la cephalosporine et procede de preparation
|
AT308173B
(de)
|
1970-02-03 |
1973-06-25 |
Maurer Friedrich Soehne |
Überbrückungsvorrichtung für Dehnungsfugen in Brücken od. dgl.
|
US4110355A
(en)
|
1972-12-26 |
1978-08-29 |
Polaroid Corporation |
Anthraquinone compounds useful in photographic processes
|
US3931145A
(en)
|
1972-12-27 |
1976-01-06 |
Gaf Corporation |
Keto-amido containing phenylazophenyl dyestuffs
|
GB1433774A
(en)
|
1973-02-26 |
1976-04-28 |
Allen & Hanburys Ltd |
Heterocyclic compounds apparatus for conveying articles
|
GB1433151A
(en)
|
1973-04-05 |
1976-04-22 |
Allen & Hanburys Ltd |
Benzo-ij-quinolizines
|
FR2281761A1
(fr)
*
|
1974-08-13 |
1976-03-12 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
FR2324304A2
(fr)
|
1975-09-22 |
1977-04-15 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
FR2340092A2
(fr)
|
1976-02-09 |
1977-09-02 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
FR2340735A1
(fr)
*
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
EP0000291B1
(en)
*
|
1977-06-28 |
1981-09-30 |
University of Strathclyde |
A pharmaceutical composition for tropical diseases
|
DE2808070A1
(de)
|
1978-02-24 |
1979-08-30 |
Bayer Ag |
Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
|
FR2443467A1
(fr)
|
1978-12-08 |
1980-07-04 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
US4312870A
(en)
*
|
1979-06-21 |
1982-01-26 |
Ciba-Geigy Corporation |
Pyrazoloquinolines
|
JPS56110612A
(en)
*
|
1980-02-08 |
1981-09-01 |
Yamanouchi Pharmaceut Co Ltd |
Readily disintegrable and absorbable compression molded article of slightly soluble drug
|
US4390541A
(en)
|
1980-12-19 |
1983-06-28 |
Lilly Industries Limited |
Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
|
HU190796B
(en)
*
|
1981-06-12 |
1986-11-28 |
Roussel Uclaf,Fr |
Process for producing n-dihydrothiazolyl-3-quinoline-carboxamide derivatives
|
FR2509728A1
(fr)
*
|
1981-07-17 |
1983-01-21 |
Roussel Uclaf |
Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
|
US5281612A
(en)
|
1982-09-09 |
1994-01-25 |
Warner-Lambert Company |
Naphthyridine antibacterial agents
|
US4638067A
(en)
|
1982-09-09 |
1987-01-20 |
Warner-Lambert Co. |
Antibacterial agents
|
FR2537140B1
(fr)
|
1982-12-07 |
1986-07-18 |
Roussel Uclaf |
Nouveaux derives de la 4-hydroxy-3-quinoleine carboxamide, leur sels, procede de preparation, application a titre de medicaments, et compositions les renfermant
|
SU1360584A3
(ru)
|
1983-08-12 |
1987-12-15 |
Варнер-Ламберт Компани (Фирма) |
Способ получени нафтиридинхинолин-или бензоксазинкарбоновых кислот или их фармацевтически допустимых солей присоединени кислоты
|
US4845105A
(en)
*
|
1984-10-30 |
1989-07-04 |
Roussel Uclaf |
4-OH-quinoline carboxylic acid amides having analgesic and anti-inflammatory activity
|
DE3571251D1
(en)
|
1984-11-01 |
1989-08-03 |
Ciba Geigy Ag |
Coatings stabilized against the action of light
|
US4687539A
(en)
|
1986-10-29 |
1987-08-18 |
International Business Machines Corp. |
End point detection and control of laser induced dry chemical etching
|
DE3702393A1
(de)
*
|
1987-01-28 |
1988-08-11 |
Bayer Ag |
8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel
|
DD279887A1
(de)
|
1987-07-03 |
1990-06-20 |
Inst Pharmakologische Forschun |
Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
|
US4777252A
(en)
*
|
1987-08-13 |
1988-10-11 |
E. R. Squibb & Sons, Inc. |
2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
|
DE3827253A1
(de)
|
1987-08-20 |
1989-03-02 |
Sandoz Ag |
Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
|
PL156390B1
(pl)
|
1987-08-27 |
1992-03-31 |
Suitomo Chemical Co Ltdjp |
Sposób wytwarzania nowej 2-fluoro- 4-/1,1,2,2-czterofluoroetoksy/ aniliny PL
|
DE3731516A1
(de)
|
1987-09-18 |
1989-03-30 |
Bayer Ag |
N-aryl-stickstoffheterocyclen
|
DE3811341A1
(de)
*
|
1987-10-09 |
1989-04-27 |
Bayer Ag |
In 7-stellung c-verknuepfte chinolon- und 1,8-naphthyridin-4-on-carbonsaeure und ein verfahren zu ihrer herstellung
|
US4786644A
(en)
*
|
1987-11-27 |
1988-11-22 |
Hoechst-Roussel Pharmaceuticals Inc. |
1-aryl-3-quinolinecarboxamide
|
DE3808117A1
(de)
|
1988-03-11 |
1989-09-21 |
Bayer Ag |
N-cyclopropylaniline und deren verwendung in verfahren zur herstellung von 1-cyclopropyl-chinoloncarbonsaeuren und deren derivaten
|
DE3808118A1
(de)
|
1988-03-11 |
1989-09-21 |
Bayer Ag |
Verfahren zur herstellung von 1-cyclopropyl-chinoloncarbonsaeuren und deren derivaten
|
DE3816119A1
(de)
|
1988-05-11 |
1989-11-23 |
Bayer Ag |
7-substituierte chinolon- und naphthyridoncarbonsaeure-derivate
|
JPH01287066A
(ja)
|
1988-05-13 |
1989-11-17 |
Fujimoto Seiyaku Kk |
新規なアントラニル酸誘導体
|
JPH01168920U
(pt)
|
1988-05-18 |
1989-11-29 |
|
|
DK273689A
(da)
*
|
1988-06-06 |
1989-12-07 |
Sanofi Sa |
4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
|
DE3827221A1
(de)
|
1988-08-11 |
1990-02-15 |
Bayer Ag |
Substituierte n-phenyl-stickstoff- bzw. stickstoff-schwefel-heterocyclen, verfahren sowie entsprechende heterocyclische phenolderivate, phenyliso(thio)cyanate und -carbamate als zwischenprodukte zu ihrer herstellung, ihre verwendung in herbiziden und pflanzenwuchsregulierenden mitteln
|
US5491139A
(en)
*
|
1988-10-24 |
1996-02-13 |
The Procter & Gamble Company |
Antimicrobial quinolonyl lactams
|
DE3903799A1
(de)
|
1989-02-09 |
1990-08-16 |
Bayer Ag |
N-aryl-stickstoffheterocyclen
|
JPH0334977A
(ja)
|
1989-06-29 |
1991-02-14 |
Yoshitomi Pharmaceut Ind Ltd |
イミダゾリルベンゾラクタム化合物
|
DE3924052A1
(de)
|
1989-07-21 |
1991-01-24 |
Bayer Ag |
N- (indol-6-yl)-heterocyclen
|
EP0418596A3
(en)
|
1989-09-21 |
1991-10-23 |
American Cyanamid Company |
Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
|
GB2236751B
(en)
|
1989-10-14 |
1993-04-28 |
Wyeth John & Brother Ltd |
Heterocyclic compounds
|
FR2659552B2
(fr)
|
1989-10-20 |
1994-11-04 |
Oreal |
Procede de teinture des fibres keratiniques avec des aminoindoles, composition et dispositif de mise en óoeuvre.
|
LU87611A1
(fr)
*
|
1989-10-20 |
1991-05-07 |
Oreal |
Composition tinctoriale pour fibres keratiniques contenant des precurseurs de colorants par oxydation et des coupleurs amino indoliques,procedes de teinture mettant en oeuvre ces compositions et composes nouveaux
|
US5254135A
(en)
|
1989-10-20 |
1993-10-19 |
L'oreal |
Methods for dyeing keratinous fibres with aminoindoles, compositions and devices for use
|
US5304121A
(en)
|
1990-12-28 |
1994-04-19 |
Boston Scientific Corporation |
Drug delivery system making use of a hydrogel polymer coating
|
FR2662713B1
(fr)
*
|
1990-05-29 |
1994-04-08 |
Oreal |
Procede de teinture de fibres keratiniques avec un aminoindole associe a un derive quinonique.
|
US5409503A
(en)
|
1990-05-31 |
1995-04-25 |
Wella Aktiengesellschaft |
Oxidation hair dye with a content of 5-aminophenyl derivatives, process for oxidative dyeing of hair and new 5-aminophenol derivatives
|
DE4017516A1
(de)
|
1990-05-31 |
1991-12-05 |
Wella Ag |
Oxidationshaarfaerbemittel mit einem gehalt an 3-aminophenol-derivaten, verfahren zum oxidativen faerben von haaren sowie neue 3-aminophenol-derivate
|
DE4026530A1
(de)
|
1990-08-22 |
1992-02-27 |
Basf Ag |
Synergistische mittel zur regulierung des pflanzenwachstums
|
ATE161252T1
(de)
*
|
1990-09-07 |
1998-01-15 |
Schering Corp |
Antivirale und antihypertensive verbindungen
|
EP0550464A1
(en)
*
|
1990-09-07 |
1993-07-14 |
Schering Corporation |
Antiviral compounds and antihypertensive compounds
|
US5175151A
(en)
*
|
1990-09-07 |
1992-12-29 |
Schering Corporation |
Antiviral compounds and antihypertensive compounds
|
JPH04171521A
(ja)
|
1990-11-05 |
1992-06-18 |
Fujitsu Ltd |
タッチパネル
|
IL100917A0
(en)
|
1991-02-16 |
1992-11-15 |
Fisons Plc |
Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
|
RU1796623C
(ru)
|
1991-03-11 |
1993-02-23 |
Институт химии Башкирского научного центра Уральского отделения АН СССР |
Способ получени этилового эфира 6,7-дифтор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
|
CA2065106A1
(en)
|
1991-04-04 |
1992-10-05 |
Junichi Fukawa |
Silver halide photographic light-sensitive material and photographic product for film-making process
|
FR2675380A1
(fr)
|
1991-04-18 |
1992-10-23 |
Oreal |
Procede de teinture des fibres keratiniques avec des aminoindoles, a ph basique, compositions mises en óoeuvre et nouveaux composes.
|
US5938792A
(en)
|
1991-04-18 |
1999-08-17 |
L'oreal |
Process for dyeing keratinous fibers with aminoindoles and oxidation dye precursors at basic Ph's and dyeing agents
|
GB9108547D0
(en)
|
1991-04-22 |
1991-06-05 |
Fujisawa Pharmaceutical Co |
Quinoline derivatives
|
WO1992019228A1
(en)
|
1991-04-29 |
1992-11-12 |
Merck & Co., Inc. |
Optimized tablet formulation
|
CA2075154A1
(en)
*
|
1991-08-06 |
1993-02-07 |
Neelakantan Balasubramanian |
Peptide aldehydes as antithrombotic agents
|
JPH05345780A
(ja)
*
|
1991-12-24 |
1993-12-27 |
Kumiai Chem Ind Co Ltd |
ピリミジンまたはトリアジン誘導体及び除草剤
|
JPH05184185A
(ja)
|
1991-12-27 |
1993-07-23 |
Copal Electron Co Ltd |
Dcブラシレスモータ速度制御方法
|
JPH05231760A
(ja)
|
1992-02-24 |
1993-09-07 |
Sanyo Electric Co Ltd |
冷蔵庫の温度制御装置
|
US5536727A
(en)
*
|
1992-05-20 |
1996-07-16 |
Merck & Co., Inc. |
17-Ethers and thioethers of 4-aza-steroids
|
EP0649306B1
(en)
*
|
1992-05-20 |
2001-01-10 |
Merck & Co. Inc. |
Ester derivatives of 4-aza-steroids
|
JPH0672979A
(ja)
|
1992-06-08 |
1994-03-15 |
Hiroyoshi Hidaka |
アミノベンジル誘導体
|
RU2047614C1
(ru)
|
1992-06-15 |
1995-11-10 |
Джон Вайс энд Бразер Лимитед |
Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
|
US5352690A
(en)
*
|
1992-07-01 |
1994-10-04 |
Eli Lilly And Company |
1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists
|
DK0649410T3
(da)
*
|
1992-07-10 |
1997-09-15 |
Glaxo Lab Sa |
Anilidderivater.
|
US5322847A
(en)
*
|
1992-11-05 |
1994-06-21 |
Pfizer Inc. |
Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
|
WO1994014797A1
(en)
|
1992-12-23 |
1994-07-07 |
Smithkline Beecham Corporation |
Quinoline compounds and the treatment of leucotriene related diseases therewith
|
JPH06278180A
(ja)
|
1993-03-26 |
1994-10-04 |
Mitsubishi Heavy Ind Ltd |
型盤開限度ストッパ装置
|
US5750754A
(en)
*
|
1993-03-29 |
1998-05-12 |
Zeneca Limited |
Heterocyclic compounds
|
JP3760474B2
(ja)
*
|
1993-04-22 |
2006-03-29 |
ダイキン工業株式会社 |
電気エネルギーを発生させる方法、装置およびそれに用いるn−f結合を有する化合物
|
US5994341A
(en)
|
1993-07-19 |
1999-11-30 |
Angiogenesis Technologies, Inc. |
Anti-angiogenic Compositions and methods for the treatment of arthritis
|
JPH0733729A
(ja)
|
1993-07-26 |
1995-02-03 |
Kirin Brewery Co Ltd |
N−シアノ−n′−置換−アリールカルボキシイミダミド化合物の製造法
|
JPH0782498A
(ja)
|
1993-09-17 |
1995-03-28 |
Fuji Photo Film Co Ltd |
ビスアゾ化合物
|
IL111266A
(en)
*
|
1993-10-22 |
2002-03-10 |
Zeneca Ltd |
2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
JP3319838B2
(ja)
|
1993-11-12 |
2002-09-03 |
本田技研工業株式会社 |
車両のトラクション制御装置
|
JPH07179407A
(ja)
|
1993-11-12 |
1995-07-18 |
Green Cross Corp:The |
新規縮合環系化合物またはその塩、およびその医薬用途
|
US5728691A
(en)
*
|
1994-02-25 |
1998-03-17 |
Laboratorios Aranda S.A. De C.V. |
Quinolonylcarboxamidocephalosporin derivatives and pharmaceutical compositions containing them
|
FR2720397B1
(fr)
*
|
1994-05-24 |
1996-08-23 |
Laphal Laboratoires Sa |
Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
|
ITMI941099A1
(it)
|
1994-05-27 |
1995-11-27 |
Smithkline Beecham Farma |
Derivati chinolinici
|
CZ291476B6
(cs)
|
1994-05-27 |
2003-03-12 |
Smithkline Beecham S. P. A. |
N-(alfa-Ethylbenzyl)-3-hydroxy-2-fenylchinolin-4-karboxamid, farmaceutický prostředek s jeho obsahem a použití
|
EP0705835A1
(de)
|
1994-09-01 |
1996-04-10 |
Ciba-Geigy Ag |
Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione
|
AU1106195A
(en)
|
1994-11-09 |
1996-06-06 |
Novo Nordisk A/S |
Heterocyclic compounds, their preparation and use
|
JP3556982B2
(ja)
|
1994-12-15 |
2004-08-25 |
小島プレス工業株式会社 |
ラゲ−ジトレイ
|
WO1996019239A1
(fr)
*
|
1994-12-21 |
1996-06-27 |
Yamanouchi Pharmaceutical Co., Ltd. |
Composition solide a solubilite et absorbabilite ameliorees
|
GB9501567D0
(en)
*
|
1995-01-26 |
1995-03-15 |
Pharmacia Spa |
Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
|
JPH08208824A
(ja)
|
1995-01-31 |
1996-08-13 |
Idemitsu Kosan Co Ltd |
ポリカーボネートの製造方法
|
US6099562A
(en)
|
1996-06-13 |
2000-08-08 |
Schneider (Usa) Inc. |
Drug coating with topcoat
|
JPH08301849A
(ja)
|
1995-05-01 |
1996-11-19 |
Takeda Chem Ind Ltd |
ヘテロ環化合物およびその製造法
|
JPH0971534A
(ja)
|
1995-06-26 |
1997-03-18 |
Tanabe Seiyaku Co Ltd |
医薬組成物
|
DE19601142A1
(de)
|
1995-07-13 |
1997-01-16 |
Agfa Gevaert Ag |
Verfahren zur Erzeugung eines farbigen Bildes
|
EP0841927B1
(en)
*
|
1995-08-02 |
2004-01-28 |
Darwin Discovery Limited |
Quinolones and their therapeutic use
|
MX9800922A
(es)
*
|
1995-08-02 |
1998-05-31 |
Darwin Discovery Ltd |
Quinolonas y su uso terapeutico.
|
DE19532235A1
(de)
|
1995-08-31 |
1997-03-06 |
Keppler Bernhard K Priv Doz Dr |
An Phosphonsäuren gekoppelte antibakteriell wirksame Verbindungen zur Therapie von Infektionen im Bereich des Knochens
|
CN1200114A
(zh)
*
|
1995-10-19 |
1998-11-25 |
武田药品工业株式会社 |
作为gnrh拮抗剂的喹啉衍生物
|
NZ325248A
(en)
|
1995-12-23 |
1999-09-29 |
Pfizer Res & Dev |
Quinoline and quinazoline compounds useful in therapy
|
AU710825B2
(en)
|
1996-02-21 |
1999-09-30 |
Darwin Discovery Limited |
Quinolones and their therapeutic use
|
US6215016B1
(en)
*
|
1996-03-27 |
2001-04-10 |
Toray Industries, Inc. |
Ketone derivatives and medical application thereof
|
DE19615262A1
(de)
*
|
1996-04-18 |
1997-10-23 |
Bayer Ag |
Heteroverknüpfte Phenylglycinolamide
|
SK283162B6
(sk)
*
|
1996-05-20 |
2003-03-04 |
Darwin Discovery Limited |
Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom
|
WO1997044322A1
(en)
*
|
1996-05-20 |
1997-11-27 |
Darwin Discovery Limited |
Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
|
EP0912549A4
(en)
*
|
1996-06-20 |
2002-01-02 |
Univ Texas |
CONNECTIONS AND METHOD FOR PROVIDING ACTIVE PREPARATIONS AND THE USE THEREOF
|
CA2260983A1
(en)
*
|
1996-07-23 |
1998-01-29 |
Charles A. Blum |
Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
|
GB9717576D0
(en)
*
|
1997-08-19 |
1997-10-22 |
Xenova Ltd |
Pharmaceutical compounds
|
US6069151A
(en)
*
|
1996-11-06 |
2000-05-30 |
Darwin Discovery, Ltd. |
Quinolines and their therapeutic use
|
DE19651099A1
(de)
|
1996-12-09 |
1998-06-10 |
Consortium Elektrochem Ind |
Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
|
WO1998031226A1
(de)
|
1997-01-15 |
1998-07-23 |
Novartis Ag |
Herbizides mittel
|
US5948814A
(en)
|
1997-02-20 |
1999-09-07 |
The Curators Of The University Of Missouri |
Genistein for the treatment of cystic fibrosis
|
ZA986594B
(en)
|
1997-07-25 |
1999-01-27 |
Abbott Lab |
Urokinase inhibitors
|
US6258822B1
(en)
*
|
1997-08-06 |
2001-07-10 |
Abbott Laboratories |
Urokinase inhibitors
|
ES2287971T3
(es)
*
|
1997-08-11 |
2007-12-16 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
|
EP0998272B1
(en)
|
1997-08-26 |
2003-05-02 |
Aventis Pharmaceuticals Inc. |
Pharmaceutical composition for combination of piperidinoalkanol-decongestant
|
US20020017295A1
(en)
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US6429207B1
(en)
*
|
1997-11-21 |
2002-08-06 |
Nps Pharmaceuticals, Inc. |
Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
|
ID26956A
(id)
|
1997-12-22 |
2001-02-22 |
Bayer Ag |
Pencegahan raf kinase menggunakan simetris dan nonsimetris yang digantikan diphenil urea
|
WO1999046267A1
(en)
|
1998-03-12 |
1999-09-16 |
Novo Nordisk A/S |
Modulators of protein tyrosine phosphatases (ptpases)
|
JP2004500308A
(ja)
|
1998-03-12 |
2004-01-08 |
ノボ ノルディスク アクティーゼルスカブ |
プロテインチロシンホスアターゼのモジュレーター
|
DE19818614A1
(de)
*
|
1998-04-20 |
1999-10-21 |
Basf Ag |
Neue substituierte Amide, deren Herstellung und Anwendung
|
JP2000016982A
(ja)
|
1998-06-30 |
2000-01-18 |
Kumiai Chem Ind Co Ltd |
キノリン誘導体及びこれを有効成分とする除草剤
|
US6133285A
(en)
*
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
CA2338827A1
(en)
*
|
1998-07-28 |
2000-02-10 |
Hideo Takaishi |
Fused heterocyclic dicarboxylic acids diamide derivatives or salts thereof, herbicide and method for using the same
|
ATE250057T1
(de)
*
|
1998-08-03 |
2003-10-15 |
Applied Research Systems |
Verfahren zur herstellung von 1-(1h)- benzoquinolizin-3-on derivaten
|
US7001770B1
(en)
|
1998-10-15 |
2006-02-21 |
Canji, Inc. |
Calpain inhibitors and their applications
|
JP2002528533A
(ja)
|
1998-10-29 |
2002-09-03 |
ブリストル−マイヤーズ スクイブ カンパニー |
酵素impdhの新規なインヒビター
|
FR2786483B1
(fr)
*
|
1998-12-01 |
2001-02-16 |
Rhodia Chimie Sa |
Procede de preparation de 4-hydroxyquinoleines et/ou formes tautomeres
|
US6248736B1
(en)
|
1999-01-08 |
2001-06-19 |
Pharmacia & Upjohn Company |
4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
|
US6248739B1
(en)
|
1999-01-08 |
2001-06-19 |
Pharmacia & Upjohn Company |
Quinolinecarboxamides as antiviral agents
|
PT1033364E
(pt)
|
1999-03-01 |
2005-07-29 |
Pfizer Prod Inc |
Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
|
JP2000256358A
(ja)
|
1999-03-10 |
2000-09-19 |
Yamanouchi Pharmaceut Co Ltd |
ピラゾール誘導体
|
ES2235883T3
(es)
|
1999-05-06 |
2005-07-16 |
Neurogen Corporation |
4-oxo-quinolino-3-carboxamidas sustituidas: ligandos de receptores cerebrales gaba.
|
AR028299A1
(es)
|
1999-09-17 |
2003-05-07 |
Novartis Ag |
Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
|
US6395750B1
(en)
*
|
1999-10-25 |
2002-05-28 |
Active Biotech Ab |
Drugs for the treatment of malignant tumors
|
SE0002320D0
(sv)
|
1999-10-25 |
2000-06-21 |
Active Biotech Ab |
Malignant tumors
|
ATE312820T1
(de)
|
1999-10-28 |
2005-12-15 |
Trine Pharmaceuticals Inc |
Pumpeninhibitoren zur freisetzung von medikamenten
|
WO2001034570A1
(fr)
|
1999-11-08 |
2001-05-17 |
Sankyo Company, Limited |
Derives heterocycliques azotes
|
JP2001199965A
(ja)
|
1999-11-08 |
2001-07-24 |
Sankyo Co Ltd |
含窒素複素環誘導体
|
UA75055C2
(uk)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
CO5261615A1
(es)
*
|
1999-12-01 |
2003-03-31 |
Agouron Pharma |
Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
|
ATE321045T1
(de)
|
1999-12-23 |
2006-04-15 |
|
Methoden und zusammensetzungen zur behandlung von schmerzen
|
JP2001233859A
(ja)
|
2000-02-23 |
2001-08-28 |
Yamanouchi Pharmaceut Co Ltd |
抗ヘリコバクター・ヒ゜ロリ化合物の新規製造法及びその中間体
|
AR028253A1
(es)
|
2000-03-16 |
2003-04-30 |
Pfizer Prod Inc |
Inhibidores de la glucogeno fosforilasa
|
GB0011409D0
(en)
*
|
2000-05-11 |
2000-06-28 |
Smithkline Beecham Plc |
Novel compounds
|
CA2405972C
(en)
|
2000-05-17 |
2010-03-23 |
Gottfried Seifert |
Process for the preparation of aniline compounds
|
US6800297B2
(en)
*
|
2000-06-15 |
2004-10-05 |
Acusphere, Inc. |
Porous COX-2 inhibitor matrices and methods of manufacture thereof
|
AU2001268691A1
(en)
|
2000-06-29 |
2002-01-21 |
Clairol Incorporated |
Iodo-containing organic couplers for use in oxidative hair dyeing
|
PL360398A1
(en)
|
2000-07-13 |
2004-09-06 |
Takeda Chemical Industries, Ltd. |
Lipid-rich plaque inhibitors
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
WO2002012189A1
(fr)
*
|
2000-08-09 |
2002-02-14 |
Mitsubishi Pharma Corporation |
Composes amide bicycliques condenses et utilisations medicales associees
|
WO2002038126A2
(en)
|
2000-11-08 |
2002-05-16 |
Aeromatic-Fielder Ag |
A process for production of particles for pharmaceutical compositions having increased bioavailability
|
JP2002212179A
(ja)
|
2001-01-15 |
2002-07-31 |
Wakunaga Pharmaceut Co Ltd |
新規アニリド誘導体又はその塩及びこれを含有する医薬
|
GB2372986A
(en)
|
2001-01-17 |
2002-09-11 |
Xenova Ltd |
2-oxo, 4-hydroxy pyrroles and quinolines
|
GB0102687D0
(en)
*
|
2001-02-02 |
2001-03-21 |
Pharmacia & Upjohn Spa |
Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
TWI243164B
(en)
*
|
2001-02-13 |
2005-11-11 |
Aventis Pharma Gmbh |
Acylated indanyl amines and their use as pharmaceuticals
|
DE10108271A1
(de)
*
|
2001-02-21 |
2002-08-22 |
Schering Ag |
Chinolin-, Isochinolin- und Phthalazinderivate als Antagonisten des Gonadotropin freisetzenden Hormons
|
US6515001B2
(en)
*
|
2001-03-05 |
2003-02-04 |
Chemokine Therapeutic Corporation |
IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
|
DE10110750A1
(de)
*
|
2001-03-07 |
2002-09-12 |
Bayer Ag |
Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
|
ES2292758T3
(es)
|
2001-03-29 |
2008-03-16 |
Eli Lilly And Company |
N-(2-ariletil) bencilaminas como antagonistas del receptor 5-ht6.
|
JP2002296731A
(ja)
|
2001-03-30 |
2002-10-09 |
Fuji Photo Film Co Ltd |
熱現像カラー画像記録材料
|
US6878713B2
(en)
*
|
2001-04-25 |
2005-04-12 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
JP2002322054A
(ja)
|
2001-04-26 |
2002-11-08 |
Dai Ichi Seiyaku Co Ltd |
薬剤排出ポンプ阻害薬
|
JP2002322154A
(ja)
|
2001-04-27 |
2002-11-08 |
Dai Ichi Seiyaku Co Ltd |
抗真菌化合物
|
JP2002326935A
(ja)
|
2001-05-07 |
2002-11-15 |
Sankyo Co Ltd |
含窒素複素環誘導体を含有する医薬
|
CA2448076A1
(en)
|
2001-05-24 |
2002-11-28 |
Masahiko Hayakawa |
3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
|
JP2003012667A
(ja)
|
2001-06-26 |
2003-01-15 |
Rrf Kenkyusho:Kk |
キノリンカルボキサミド骨格を有する抗菌剤
|
US20030100501A1
(en)
|
2001-09-21 |
2003-05-29 |
Case Western Reserve University |
Q4N2NEG2 enhances CFTR activity
|
CA2462442A1
(en)
*
|
2001-10-12 |
2003-04-24 |
Warner-Lambert Company Llc |
Alkyne matrix metalloproteinase inhibitors
|
JP3748222B2
(ja)
|
2001-11-07 |
2006-02-22 |
株式会社リコー |
可逆性感熱発色組成物及びそれを用いた可逆性記録媒体
|
MXPA04004657A
(es)
|
2001-11-14 |
2004-08-13 |
Teva Pharma |
Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
|
TW200300349A
(en)
|
2001-11-19 |
2003-06-01 |
Sankyo Co |
A 4-oxoqinoline derivative
|
US7084156B2
(en)
*
|
2001-11-27 |
2006-08-01 |
Merck & Co., Inc. |
2-Aminoquinoline compounds
|
WO2003049702A2
(en)
*
|
2001-12-10 |
2003-06-19 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
AU2003239463B2
(en)
|
2002-02-01 |
2007-10-18 |
Pfizer Products Inc. |
Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
JP2003238413A
(ja)
|
2002-02-14 |
2003-08-27 |
Kyowa Hakko Kogyo Co Ltd |
ステロイドスルファターゼ阻害剤
|
DE20221945U1
(de)
*
|
2002-03-15 |
2009-10-15 |
Wella Aktiengesellschaft |
Chinolinium-Salze enthaltende Färbemittel
|
US6930131B2
(en)
*
|
2002-04-10 |
2005-08-16 |
Wyeth |
Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM)
|
BR0309558A
(pt)
*
|
2002-04-26 |
2005-03-01 |
Nippon Shinyaku Co Ltd |
Derivados de quinazolina e medicamentos
|
US7037913B2
(en)
*
|
2002-05-01 |
2006-05-02 |
Bristol-Myers Squibb Company |
Bicyclo 4.4.0 antiviral derivatives
|
DE60326341D1
(de)
*
|
2002-05-14 |
2009-04-09 |
Xenova Ltd |
Verfahren zur herstellung von anthranilsäurederivat-hydrat
|
DE60325347D1
(de)
*
|
2002-05-14 |
2009-01-29 |
Univ California |
Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen
|
SE0201669D0
(sv)
|
2002-06-03 |
2002-06-03 |
Pharmacia Ab |
New formulation and use thereof
|
AU2003251944B2
(en)
*
|
2002-07-15 |
2008-06-26 |
Myriad Genetics, Inc. |
Compounds, compositions, and methods employing same
|
US20040033959A1
(en)
*
|
2002-07-19 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pharmaceutical compositions for hepatitis C viral protease inhibitors
|
WO2004014377A1
(en)
*
|
2002-08-13 |
2004-02-19 |
Warner-Lambert Company Llc |
4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
|
TWI314041B
(en)
|
2002-10-21 |
2009-09-01 |
Sankyo Agro Co Ltd |
Quinolyl-3-carboxamide compound
|
AR042206A1
(es)
|
2002-11-26 |
2005-06-15 |
Novartis Ag |
Acidos fenilaceticos y derivados
|
JP2004189738A
(ja)
|
2002-11-29 |
2004-07-08 |
Nippon Nohyaku Co Ltd |
置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法
|
WO2004080972A1
(en)
|
2003-03-12 |
2004-09-23 |
Vertex Pharmaceuticals Incorporated |
Pirazole modulators of atp-binding cassette transporters
|
WO2004105779A2
(en)
|
2003-05-27 |
2004-12-09 |
Cesare Montecucco |
Green tea and oplyphenol inhibitors of bacterial proteases
|
WO2004111014A1
(en)
|
2003-06-06 |
2004-12-23 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine derivatives as modulators of atp-binding cassette transporters
|
EP1650192A4
(en)
*
|
2003-07-24 |
2007-03-21 |
Astellas Pharma Inc |
QUINOLONE DERIVATIVE OR SALT THEREOF
|
CN1191252C
(zh)
|
2003-08-11 |
2005-03-02 |
中国药科大学 |
3-位取代的喹诺酮衍生物及其在药学上的应用
|
RU2006111093A
(ru)
|
2003-09-06 |
2007-10-27 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Модуляторы атр-связывающих кассетных транспортеров
|
US20050059035A1
(en)
|
2003-09-09 |
2005-03-17 |
Quest Diagnostics Incorporated |
Methods and compositions for the amplification of mutations in the diagnosis of cystic fibrosis
|
SG146608A1
(en)
|
2003-09-12 |
2008-10-30 |
Amgen Inc Dw Us |
Rapid dissolution formulation of a calcium receptor-active compound
|
WO2005028467A1
(en)
|
2003-09-15 |
2005-03-31 |
Anadys Pharmaceuticals, Inc. |
Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
|
JP2007509044A
(ja)
|
2003-10-08 |
2007-04-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
シクロアルキルピラニル基を含むatp結合カセットトランスポーターのモジュレータ
|
US7407976B2
(en)
|
2003-11-14 |
2008-08-05 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters
|
ATE495746T1
(de)
|
2003-11-14 |
2011-02-15 |
Ajinomoto Kk |
Feste dispersion oder medizinisches festes dispersionspräparat eines phenylalanin-derivats
|
US20050208095A1
(en)
*
|
2003-11-20 |
2005-09-22 |
Angiotech International Ag |
Polymer compositions and methods for their use
|
EP1727520A2
(en)
|
2003-12-09 |
2006-12-06 |
Medcrystalforms, Llc |
Method of preparation of mixed phase co-crystals with active agents
|
US20070196395A1
(en)
|
2003-12-12 |
2007-08-23 |
Mackerell Alexander |
Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
JP2007519756A
(ja)
*
|
2004-01-30 |
2007-07-19 |
アンジオテック インターナショナル アーゲー |
拘縮を治療するための組成物および方法
|
AU2005210474B2
(en)
|
2004-01-30 |
2011-07-07 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding cassette transporters
|
SE0400235D0
(sv)
*
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
WO2005094805A1
(ja)
|
2004-04-01 |
2005-10-13 |
Institute Of Medicinal Molecular Design. Inc. |
イミン誘導体及びアミド誘導体
|
JP2006206612A
(ja)
|
2004-05-27 |
2006-08-10 |
Ono Pharmaceut Co Ltd |
固形製剤用組成物
|
EP1765347A4
(en)
*
|
2004-06-04 |
2008-10-01 |
Univ California |
COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE
|
LT2489659T
(lt)
|
2004-06-24 |
2018-03-26 |
Vertex Pharmaceuticals Incorporated |
Atp rišančios kasetės transporterių moduliatoriai
|
US20140343098A1
(en)
|
2004-06-24 |
2014-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
EP1771158A4
(en)
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
TABLET FOR PULSED DELIVERY
|
US20060035890A1
(en)
|
2004-08-10 |
2006-02-16 |
Amit Banerjee |
Compounds and methods for the treatment of ubiquitin conjugating disorders
|
AU2005286719B2
(en)
|
2004-09-21 |
2011-03-24 |
Bone Solutions, Inc. |
Multi-purpose bio-material composition
|
CA2588607A1
(en)
|
2004-11-23 |
2006-06-01 |
Ptc Therapeutics, Inc. |
Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
|
EP2363128B1
(en)
|
2005-03-11 |
2016-02-17 |
Vertex Pharmaceuticals Incorporated |
Indole modulators of ATP-binding cassette transporters
|
CN101605543A
(zh)
|
2005-03-18 |
2009-12-16 |
加利福尼亚大学董事会 |
具有校正突变-cftr加工活性的化合物及其应用
|
KR20080005575A
(ko)
|
2005-04-28 |
2008-01-14 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
안정화 조성물
|
AU2006251624A1
(en)
|
2005-05-24 |
2006-11-30 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding cassette transporters
|
MX2008002019A
(es)
|
2005-08-11 |
2008-04-16 |
Vertex Pharma |
Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
|
CN101287732A
(zh)
|
2005-08-11 |
2008-10-15 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜电导调节剂的调控剂
|
WO2007044560A2
(en)
|
2005-10-06 |
2007-04-19 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
SI2404919T1
(sl)
|
2005-11-08 |
2013-12-31 |
Vertex Pharmaceuticals Incorporated |
Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
|
US20120232059A1
(en)
|
2005-11-08 |
2012-09-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette Transporters
|
US20080057047A1
(en)
|
2005-11-29 |
2008-03-06 |
Benedikt Sas |
Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
|
US7989430B2
(en)
|
2005-12-06 |
2011-08-02 |
Regents Of The University Of Minnesota |
Antibacterial agents
|
US20090105272A1
(en)
|
2005-12-24 |
2009-04-23 |
Grootenhuis Peter D J |
Prodrugs of modulators of ABC transporters
|
EP1978939A2
(en)
|
2005-12-27 |
2008-10-15 |
Jubilant Organosys Limited |
Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
|
WO2007075946A1
(en)
|
2005-12-27 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in cftr assays and methods therewith
|
CA2635760C
(en)
|
2005-12-28 |
2014-07-15 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
RS60205B1
(sr)
|
2005-12-28 |
2020-06-30 |
Vertex Pharma |
Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
|
UY30118A1
(es)
|
2006-01-31 |
2007-06-29 |
Tanabe Seiyaku Co |
Compueto amina trisustituido
|
PL2383271T3
(pl)
|
2006-03-13 |
2013-12-31 |
Kyorin Seiyaku Kk |
Aminochinolony jako inhibitory GSK-3
|
WO2007106957A1
(en)
|
2006-03-21 |
2007-09-27 |
Laboratoires Smb S.A. |
Multiple units controlled-release floating dosage forms
|
MX2008012945A
(es)
|
2006-04-07 |
2009-01-15 |
Vertex Pharma |
Moduladores de transportadores de cartucho de union a adenosina-trifosfato celular (atp).
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
EP2687516A1
(en)
|
2006-04-20 |
2014-01-22 |
Janssen Pharmaceutica N.V. |
Inhibitors of C-FMS Kinase
|
JP2009536969A
(ja)
*
|
2006-05-12 |
2009-10-22 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミド組成物
|
CN101516355A
(zh)
|
2006-09-12 |
2009-08-26 |
葛兰素集团有限公司 |
包括多个含有因子Xa抑制剂的微型片剂的药物组合物
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
CA2668305C
(en)
|
2006-11-03 |
2017-01-03 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as cftr modulators
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
MX2009006806A
(es)
|
2006-12-22 |
2009-08-27 |
Vertex Pharma |
Secado por rocio fluidizado.
|
WO2008083130A2
(en)
|
2006-12-26 |
2008-07-10 |
Dr. Reddy's Laboratories Limited |
Amorphous and crystalline form a of carvedilol phosphate
|
JP5412423B2
(ja)
*
|
2007-04-18 |
2014-02-12 |
コーナーストーン ファーマシューティカルズ,インコーポレーテッド |
リポ酸誘導体
|
CA2686838C
(en)
|
2007-05-09 |
2017-03-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cftr
|
WO2008147952A1
(en)
|
2007-05-25 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
JP4834699B2
(ja)
|
2007-07-30 |
2011-12-14 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP4846769B2
(ja)
|
2007-07-30 |
2011-12-28 |
田辺三菱製薬株式会社 |
医薬組成物
|
US20110177999A1
(en)
|
2007-08-09 |
2011-07-21 |
Vertex Pharmaceuticals Incorporated |
Therapeutic Combinations Useful in Treating CFTR Related Diseases
|
NZ583420A
(en)
|
2007-08-24 |
2012-06-29 |
Vertex Pharma |
Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
|
BRPI0816345A2
(pt)
|
2007-09-14 |
2015-02-24 |
Vertex Pharma |
Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida
|
ES2445442T3
(es)
|
2007-09-14 |
2014-03-03 |
Vertex Pharmaceuticals Inc. |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
NZ585980A
(en)
|
2007-11-16 |
2012-04-27 |
Vertex Pharma |
Isoquinoline modulators of atp-binding cassette transporters
|
CA2706920C
(en)
|
2007-12-07 |
2018-02-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
CA2708146A1
(en)
|
2007-12-07 |
2009-06-18 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
PT2639222T
(pt)
|
2007-12-07 |
2016-11-01 |
Vertex Pharma |
Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos
|
CN101925603B
(zh)
|
2007-12-13 |
2013-12-04 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜通道调节因子的调节剂
|
ES2647531T3
(es)
|
2008-02-28 |
2017-12-22 |
Vertex Pharmaceuticals Incorporated |
Derivados de heteroarilo como moduladores de CFTR
|
CA2718310C
(en)
|
2008-03-31 |
2018-08-07 |
Vertex Pharmaceuticals Incorporated |
Pyridyl derivatives as cftr modulators
|
US20100256184A1
(en)
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
RS56894B1
(sr)
|
2008-08-13 |
2018-04-30 |
Vertex Pharma |
Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
|
EP2328609A1
(en)
|
2008-08-26 |
2011-06-08 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Rapidly disintegrating tablets comprising lipase, amylase, and protease
|
CN102164587A
(zh)
|
2008-09-29 |
2011-08-24 |
沃泰克斯药物股份有限公司 |
3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元
|
PT2344129T
(pt)
|
2008-10-07 |
2018-04-23 |
Horizon Orphan Llc |
Formulações de fluoroquinolona em aerossol para farmacocinética melhorada
|
CN102325532B
(zh)
|
2008-10-07 |
2015-06-17 |
Mpex医药有限公司 |
用于减轻肺部炎症的左氧氟沙星吸入剂
|
US9333235B2
(en)
|
2008-10-22 |
2016-05-10 |
Trustees Of Dartmouth College |
Combination therapy and kit for the prevention and treatment of cystic fibrosis
|
PT2349263E
(pt)
|
2008-10-23 |
2014-07-28 |
Vertex Pharma |
Moduladores de regulador da condutância transmembranar da fibrose cística
|
JP5645835B2
(ja)
|
2008-10-23 |
2014-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
N−(4−(7−アザビシクロ[2.2.1]ヘプタン−7−イル)−2−(トリフルオロメチル)フェニル)−4−オキソ−5−(トリフルオロメチル)−1,4−ジヒドロキノリン−3−カルボキサミドの固体形態
|
US20110257223A1
(en)
|
2008-10-23 |
2011-10-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
|
AU2009308232B2
(en)
|
2008-10-23 |
2016-02-04 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2010053471A1
(en)
|
2008-11-06 |
2010-05-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
JP5699090B2
(ja)
|
2008-12-30 |
2015-04-08 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
|
GB201111244D0
(en)
|
2011-06-30 |
2011-08-17 |
Konink Nl Akademie Van Wetenschappen Knaw |
Culture media for stem cells
|
JP2012520683A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害
|
JP2012520685A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害
|
JP2012520686A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたシグナル伝達性転写因子6(STAT6)遺伝子発現のRNA干渉媒介性阻害
|
SG174452A1
(en)
|
2009-03-19 |
2011-10-28 |
Merck Sharp & Dohme |
RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
|
SI2408749T1
(sl)
|
2009-03-20 |
2018-10-30 |
Vertex Pharmaceuticals Incorporated |
Modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi
|
KR101955863B1
(ko)
|
2009-03-20 |
2019-03-07 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EP2411516A1
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2411517A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2411520A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2411518A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Rna interference mediated inhibition of the high affinity ige receptor alpha chain (fcerla) gene expression using short interfering nucleic acid (sina)
|
RU2543622C2
(ru)
|
2009-09-17 |
2015-03-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения азабициклических соединений
|
CN102665715A
(zh)
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
BR112012009583A2
(pt)
|
2009-10-23 |
2015-09-29 |
Vertex Pharma |
processo para preparação de moduladores de regulador de condutância de transmembrana de fibrose cística
|
RU2568608C2
(ru)
|
2009-10-23 |
2015-11-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида
|
US20130004477A1
(en)
|
2009-10-26 |
2013-01-03 |
Zhe Lu |
Methods for Treating Inflammation and Oxidative Stress Related Diseases
|
WO2011072275A2
(en)
|
2009-12-11 |
2011-06-16 |
Nono, Inc. |
Agents and methods for treating ischemic and other diseases
|
US20110183948A1
(en)
|
2010-01-15 |
2011-07-28 |
Infinity Pharmaceuticals, Inc. |
Treatment of fibrotic conditions using hedgehog inhibitors
|
US20150152348A1
(en)
|
2010-02-26 |
2015-06-04 |
Sharps Compliance, Inc. |
Systems and methods for collecting, transporting and repurposing or destroying unused pharmaceuticals
|
AU2011227021A1
(en)
|
2010-03-19 |
2012-10-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
NZ700556A
(en)
|
2010-03-25 |
2016-04-29 |
Vertex Pharma |
Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
|
HRP20211752T1
(hr)
|
2010-04-07 |
2022-02-18 |
Vertex Pharmaceuticals Incorporated |
Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
|
TWI549950B
(zh)
|
2010-04-07 |
2016-09-21 |
維泰克斯製藥公司 |
3-(6-(1-(2,2-二氟苯并[d][1,3]二氧雜環戊烯-5-基)環丙烷甲醯胺基)-3-甲基吡啶-2-基)苯甲酸之固體形式
|
CA2796642A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
SG10201505700QA
(en)
|
2010-04-22 |
2015-08-28 |
Vertex Pharma |
Process of producing cycloalkylcarboxamido-indole compounds
|
WO2011133953A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
AU2011242457A1
(en)
|
2010-04-22 |
2012-11-08 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
TW201202250A
(en)
|
2010-05-20 |
2012-01-16 |
Vertex Pharma |
Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
|
AU2011255237A1
(en)
|
2010-05-20 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
US20120164080A1
(en)
|
2010-06-24 |
2012-06-28 |
Meritage Pharma, Inc. |
Methods of treatment for esophageal inflammation
|
BR112013004443A8
(pt)
|
2010-08-23 |
2018-01-02 |
Vertex Pharma |
composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas
|
WO2012027731A2
(en)
|
2010-08-27 |
2012-03-01 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
WO2012030664A1
(en)
|
2010-08-30 |
2012-03-08 |
Pulmatrix, Inc. |
Dry powder formulations and methods for treating pulmonary diseases
|
US8758824B2
(en)
|
2010-08-30 |
2014-06-24 |
Pulmatrix, Inc. |
Respirably dry powder comprising calcium lactate, sodium chloride and leucine
|
US9050339B2
(en)
|
2010-09-17 |
2015-06-09 |
Novartis Ag |
Pyrazine derivatives as ENaC blockers
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
JP5937102B2
(ja)
|
2010-12-14 |
2016-06-22 |
エレクトロフォレティクス リミテッド |
カゼインキナーゼ1デルタ(ck1デルタ)阻害剤
|
USRE47009E1
(en)
|
2011-02-01 |
2018-08-28 |
The Children's Hospital Of Philadelphia |
HDAC inhibitors and therapeutic methods using the same
|
WO2012148953A1
(en)
|
2011-04-25 |
2012-11-01 |
Stc.Unm |
Solid compositions for pharmaceutical use
|
US20130072473A1
(en)
|
2011-05-09 |
2013-03-21 |
Proteostasis Therapeutics, Inc. |
Compounds for treating protein folding disorders
|
HUE032771T2
(en)
|
2011-05-18 |
2017-10-30 |
Concert Pharmaceuticals Inc |
Deuterated ivacaftor derivatives
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
ITMI20111068A1
(it)
|
2011-06-14 |
2012-12-15 |
Azienda Ospedaliera Universitaria I Ntegrata Di Ve |
Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
KR101317656B1
(ko)
|
2011-06-30 |
2013-10-15 |
연세대학교 산학협력단 |
복제효소 인산화를 조절하는 신규 c형 간염 예방 또는 치료용 조성물
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
AU2012284091B2
(en)
|
2011-07-19 |
2015-11-12 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
CN103998442B
(zh)
|
2011-08-29 |
2016-09-14 |
无限药品股份有限公司 |
杂环化合物及其用途
|
US20140336159A1
(en)
|
2011-10-07 |
2014-11-13 |
Pulmatrix, Inc. |
Methods for treating and diagnosing respiratory tract infections
|
RS56498B1
(sr)
|
2011-11-02 |
2018-01-31 |
Boehringer Ingelheim Int |
Heterociklična jedinjenja, medikamenti koji sadrže navedena jedinjenja, njihova primena i postupci za njihovo dobijanje
|
AU2012332225A1
(en)
|
2011-11-02 |
2014-05-15 |
Vertex Pharmaceuticals Incorporated |
Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases
|
WO2013070659A1
(en)
|
2011-11-07 |
2013-05-16 |
Sunovion Pharmaceuticals Inc. |
Modulators of opioid receptors and methods of use thereof
|
MX357328B
(es)
|
2011-11-08 |
2018-07-05 |
Vertex Pharma |
Moduladores de trasportadores de casete enlazante de atp.
|
US20140127901A1
(en)
|
2012-11-08 |
2014-05-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Low-k damage free integration scheme for copper interconnects
|
BR112014014674A2
(pt)
|
2011-12-16 |
2017-06-13 |
Tarix Pharmaceuticals Ltd |
angiotensinas para tratamento de fibrose
|
TR201815226T4
(tr)
|
2011-12-19 |
2018-11-21 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Birincil intestinal kültür modelindeki cftr fonksiyonunu ölçmek için hızlı ve nicel bir analiz.
|
US8859559B2
(en)
|
2011-12-20 |
2014-10-14 |
Boehringer Ingelheim International Gmbh |
Substituted pyrazines and their use in the treatment of disease
|
CA2862859C
(en)
|
2012-01-25 |
2022-08-02 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
NZ629199A
(en)
|
2012-02-27 |
2017-01-27 |
Vertex Pharma |
Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
CN104487075A
(zh)
|
2012-02-29 |
2015-04-01 |
普马特里克斯公司 |
可吸入干粉剂
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
CA2869257A1
(en)
|
2012-04-06 |
2013-10-10 |
The Uab Research Foundation |
Methods for increasing cftr activity
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013157018A1
(en)
|
2012-04-18 |
2013-10-24 |
Indian Institute Of Technology Madras |
A process for the preparation of the core structure in quinolone and napthyridone class of antibiotics
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
EP2659890A1
(en)
|
2012-04-30 |
2013-11-06 |
Orphan Synergy Europe - Pharma |
Methods and compositions for the treatment of fibrosis
|
ES2656321T3
(es)
|
2012-05-17 |
2018-02-26 |
I.E.R.F.C. European Institute For Cystic Fibrosis Research |
Terapia combinada para fibrosis quística
|
FR2990859B1
(fr)
|
2012-05-24 |
2014-05-23 |
Gaetan Terrasse |
Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
|
JP6204977B2
(ja)
|
2012-05-25 |
2017-09-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
三級アミン、前記アミンを含む薬物、その使用及びその調製方法
|
ES2897825T3
(es)
|
2012-06-01 |
2022-03-02 |
Icahn School Med Mount Sinai |
Niveles de ceramida en el tratamiento y prevención de infecciones
|
DE102012209523A1
(de)
|
2012-06-06 |
2013-12-12 |
Osram Opto Semiconductors Gmbh |
Hauptgruppenmetallkomplexe als p-Dotanden für organische elektronische Matrixmaterialien
|
DE102012209520A1
(de)
|
2012-06-06 |
2013-12-12 |
Osram Opto Semiconductors Gmbh |
Metallkomplexe als p-Dotanden für organische elektronische Matrixmaterialien
|
AU2013270681A1
(en)
|
2012-06-08 |
2014-12-18 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of CFTR -mediated disorders
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
US20150209448A1
(en)
|
2012-07-12 |
2015-07-30 |
Proqr Therapeutics N.V. |
Exon replacement with stabilized artificial rnas
|
PL2852668T3
(pl)
|
2012-07-12 |
2016-11-30 |
|
Oligonukleotydy do wprowadzania zmian w sekwencji docelowej cząsteczki RNA obecnej w żywej komórce
|
US9012496B2
(en)
|
2012-07-16 |
2015-04-21 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
|
JP6186434B2
(ja)
|
2012-07-18 |
2017-08-23 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. |
窒素複素環誘導体及びその医薬品への応用
|
ES2603262T3
(es)
|
2012-07-20 |
2017-02-24 |
Bayer Pharma Aktiengesellschaft |
Ácidos aminoindano-carboxílicos y aminotetralin-carboxílicos sustituidos y su uso
|
MX360863B
(es)
|
2012-07-20 |
2018-11-09 |
Bayer Pharma AG |
Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso.
|
EP2877159B8
(en)
|
2012-07-27 |
2018-02-14 |
Izumi Technology, LLC. |
Efflux inhibitor compositions and methods of treatment using the same
|
EP2882426A1
(en)
|
2012-08-13 |
2015-06-17 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for treatment of cystic fibrosis
|
US9566310B2
(en)
|
2012-09-10 |
2017-02-14 |
Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno |
Methods of treating muscular dystrophy
|
EP2897940B1
(en)
|
2012-09-24 |
2019-05-01 |
Boehringer Ingelheim International GmbH |
Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
|
EP3591052B1
(en)
|
2012-09-24 |
2023-08-30 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Restoration of the cftr function by splicing modulation
|
WO2014058974A1
(en)
|
2012-10-10 |
2014-04-17 |
Emory University |
Methods of managing inflammation using glycolysis pathway inhibitors
|
EP2906570A4
(en)
|
2012-10-15 |
2016-06-08 |
Yeda Res & Dev |
USE OF LONG-TERM SPHINGOID BASES AND THEIR ANALOGUE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS
|
US20140120060A1
(en)
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
|
RS57831B2
(sr)
|
2012-11-02 |
2024-02-29 |
Vertex Pharma |
Farmaceutske kompozicije za lečenje bolesti posredovanih sa cftr
|
JP6146990B2
(ja)
|
2012-11-16 |
2017-06-14 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたcftr増強物質
|
WO2014078842A1
(en)
|
2012-11-19 |
2014-05-22 |
Concert Pharmaceuticals, Inc. |
Deuterated cftr potentiators
|
EP2922852A4
(en)
|
2012-11-20 |
2016-05-25 |
Discoverybiomed Inc |
CFTR SMALL MOLECULE CORRECTIVES
|
EP2922853A4
(en)
|
2012-11-20 |
2016-11-23 |
Discoverybiomed Inc |
SMALL MOLECULE BICYCLIC AND TRICYCLIC CFTR CORRECTING DEVICES
|
US10034988B2
(en)
|
2012-11-28 |
2018-07-31 |
Fontem Holdings I B.V. |
Methods and devices for compound delivery
|
US20150346185A1
(en)
|
2012-12-05 |
2015-12-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Diagnosis of cystic fibrosis
|
EP2928532A4
(en)
|
2012-12-07 |
2016-06-29 |
Parion Sciences Inc |
NOSE CANNULA FOR THE ADMINISTRATION OF MEDICAMENTS IN AEROSOL FORM
|
US9029382B2
(en)
|
2012-12-17 |
2015-05-12 |
Parion Sciences, Inc. |
3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
|
CA2895239C
(en)
|
2012-12-21 |
2020-10-27 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
CN103044263A
(zh)
|
2013-01-14 |
2013-04-17 |
中国药科大学 |
一种治疗囊性纤维化药物的中间体的制备方法
|
US20140221424A1
(en)
|
2013-01-30 |
2014-08-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for use in the treatment of cystic fibrosis
|
EP2951158B1
(en)
|
2013-01-31 |
2019-05-29 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of ivacaftor and solvates thereof
|
US9573902B2
(en)
|
2013-02-15 |
2017-02-21 |
Laurus Labs Private Ltd. |
Process for the preparation of Ivacaftor and its intermediates
|
KR20240024355A
(ko)
|
2013-02-18 |
2024-02-23 |
유니버시티 헬스 네트워크 |
다능성 줄기세포로부터 간세포 및 담관세포의 생성 방법
|
CN104030981A
(zh)
|
2013-03-06 |
2014-09-10 |
上海特化医药科技有限公司 |
Ivacaftor的制备方法及其中间体
|
CN105307655B
(zh)
|
2013-03-13 |
2019-05-03 |
弗拉特利发现实验室有限责任公司 |
哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
|
WO2014160478A1
(en)
|
2013-03-13 |
2014-10-02 |
Flatley Discovery Lab |
Compounds and methods for the treatment of cystic fibrosis
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
JP6672139B2
(ja)
|
2013-03-15 |
2020-03-25 |
オアプロ セラピューティクス インコーポレイテッドOrpro Therapeutics,Inc. |
粘液の粘性の正常化のための組成物
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US20140296164A1
(en)
|
2013-03-29 |
2014-10-02 |
Calista Therapeutics, Inc. |
Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
|
CN103224466A
(zh)
|
2013-04-15 |
2013-07-31 |
北京大学 |
具有β-分泌酶抑制功能的化合物及其制备方法与应用
|
WO2014186608A1
(en)
|
2013-05-15 |
2014-11-20 |
Adverse Events, Inc. |
System and method for surveillance and evaluation of safety risks associated with medical interventions
|
WO2014186704A2
(en)
|
2013-05-17 |
2014-11-20 |
N30 Pharmaceuticals, Inc. |
Novel compounds for the treatment of cystic fibrosis
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
WO2014210159A1
(en)
|
2013-06-26 |
2014-12-31 |
Proteostasis Therapeutics, Inc. |
Methods of modulating cftr activity
|
JP6461948B2
(ja)
|
2013-07-15 |
2019-01-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規5−置換ベンゾイミダゾリウム化合物
|
WO2015007517A1
(en)
|
2013-07-15 |
2015-01-22 |
Boehringer Ingelheim International Gmbh |
Novel tetra- and pentasubstituted benzimidazolium compounds
|
WO2015007519A1
(en)
|
2013-07-15 |
2015-01-22 |
Boehringer Ingelheim International Gmbh |
Novel benzimidazolium compounds
|
US10265314B2
(en)
|
2013-07-25 |
2019-04-23 |
Bayer Pharma Aktiengesellschaft |
SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
|
EP2835423A1
(en)
|
2013-08-09 |
2015-02-11 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Ligase E3 RNF185 inhibitors and uses thereof
|
WO2015036552A1
(en)
|
2013-09-12 |
2015-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of cystic fibrosis
|
US20150099270A1
(en)
|
2013-10-04 |
2015-04-09 |
Thomas C. DOWLING |
Method of screening pharmaceuticals for drug interactions and nephrotoxicity
|
MX2021012208A
(es)
|
2013-10-04 |
2023-01-19 |
Infinity Pharmaceuticals Inc |
Compuestos heterocíclicos y usos de los mismos.
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
FR3011467B1
(fr)
|
2013-10-08 |
2016-02-12 |
Centre Nat Rech Scient |
Composes et compositions comprenant de tels composes pour la prevention ou le traitement des dyslipidemies
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20160229778A1
(en)
|
2013-11-08 |
2016-08-11 |
Board Of Regents, The University Of Texas System |
Direct b-arylation of carbonyl compounds
|
PL3068392T3
(pl)
|
2013-11-12 |
2021-07-19 |
Vertex Pharmaceuticals Incorporated |
Proces wytwarzania kompozycji farmaceutycznych do leczenia chorób, w których pośredniczy cftr
|
US9809551B2
(en)
|
2013-11-13 |
2017-11-07 |
Apotex Inc. |
Solid forms of Ivacaftor and processes for the preparation thereof
|
CN105934257B
(zh)
|
2013-12-06 |
2020-10-09 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
ES2663806T3
(es)
|
2013-12-19 |
2018-04-17 |
unshine Lake Pharma Co., Ltd. |
Derivados heterocíclicos nitrogenados y su aplicación en el tratamiento de la fibrosis tisular
|
US20160271056A1
(en)
|
2013-12-23 |
2016-09-22 |
Nitric Solutions Inc. |
Cystic fibrosis treatment comprising nitric oxide
|
PL3698832T3
(pl)
|
2014-01-22 |
2023-01-30 |
Fontem Ventures B.V. |
Sposoby i urządzenia do łagodzenia potrzeby palenia
|
MX2016010213A
(es)
|
2014-02-07 |
2017-04-13 |
Auspex Pharmaceuticals Inc |
Formulaciones farmaceuticas novedosas.
|
CN103787968B
(zh)
|
2014-02-27 |
2016-04-13 |
上海湖发化学技术有限公司 |
化合物的制备方法
|
WO2015128882A2
(en)
|
2014-02-27 |
2015-09-03 |
Msn Laboratories Private Limited |
Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof
|
CA2942386A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
EP3116870A1
(en)
|
2014-03-13 |
2017-01-18 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
CA2943075C
(en)
|
2014-03-19 |
2023-02-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
SI3131582T1
(sl)
|
2014-04-15 |
2018-09-28 |
Vertex Pharmaceuticals Incorporated |
Farmacevtski sestavki za zdravljenje bolezni, pri katerih posreduje regulator transmembranske prevodnosti
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
CA2947982C
(en)
|
2014-05-08 |
2022-11-29 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
PT3142701T
(pt)
|
2014-05-12 |
2018-10-18 |
Verona Pharma Plc |
Novo tratamento
|
ES2751773T3
(es)
|
2014-05-15 |
2020-04-01 |
Amgen Europe Gmbh |
Uso de inhibidores pde4 y combinaciones de los mismos para el tratamiento de la fibrosis quística
|
US20170087129A1
(en)
|
2014-05-16 |
2017-03-30 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
WO2015179369A1
(en)
|
2014-05-20 |
2015-11-26 |
Infinity Pharmaceuticals, Inc. |
Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors
|
US10174014B2
(en)
|
2014-06-19 |
2019-01-08 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
WO2016020305A1
(en)
|
2014-08-04 |
2016-02-11 |
Sandoz Ag |
Aqueous granulation process for amorphous poorly water soluble drugs
|
AU2015304851A1
(en)
|
2014-08-21 |
2017-02-23 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as RIP1 kinase inhibitors as medicaments
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
CN104725628B
(zh)
|
2014-10-01 |
2018-04-17 |
厦门赛诺邦格生物科技股份有限公司 |
一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
|
CN104530417B
(zh)
|
2014-10-01 |
2017-09-08 |
厦门赛诺邦格生物科技股份有限公司 |
一种多官能化h型聚乙二醇衍生物及其制备方法
|
CN104530415B
(zh)
|
2014-10-01 |
2017-09-01 |
厦门赛诺邦格生物科技股份有限公司 |
一种异官能化y型聚乙二醇衍生物、制备方法及其生物相关物质
|
CN104530413B
(zh)
|
2014-10-01 |
2017-08-25 |
厦门赛诺邦格生物科技股份有限公司 |
一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
|
US9855249B2
(en)
|
2014-10-02 |
2018-01-02 |
Flatley Discovery Lab, Llc |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
WO2016057522A1
(en)
|
2014-10-06 |
2016-04-14 |
Flatley Discovery Lab |
Triazolopyridine compounds and methods for the treatment of cystic fibrosis
|
EP3798214B1
(en)
|
2014-10-06 |
2022-09-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
RU2749213C2
(ru)
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
US20170281612A1
(en)
|
2014-10-08 |
2017-10-05 |
Nivalis Therapeutics, Inc. |
Methods for the Treatment of Cystic Fibrosis
|
US20160108406A1
(en)
|
2014-10-08 |
2016-04-21 |
University Of Iowa Research Foundation |
Method of regulating cftr expression and processing
|
GB201418892D0
(en)
|
2014-10-23 |
2014-12-10 |
Proqr Therapeutics B V |
DNA editing
|
AU2015335375B2
(en)
|
2014-10-24 |
2020-09-10 |
Launx Biomedical Co., Ltd. |
Use of azelnidipine in preparing medicinal composition for treating cancers
|
EP3212184B1
(en)
|
2014-10-31 |
2020-04-01 |
AbbVie Overseas S.à r.l. |
Substituted benzotetrahydropyrans and their use
|
SG11201703391VA
(en)
|
2014-10-31 |
2017-05-30 |
Abbvie S À R L |
Substituted chromanes and method of use
|
US10864248B2
(en)
|
2014-11-12 |
2020-12-15 |
Trustees Of Dartmouth College |
Dab2 inhibitors for the prevention and treatment of cystic fibrosis
|
WO2016075703A2
(en)
|
2014-11-13 |
2016-05-19 |
Laurus Labs Private Limited |
An improved process for preparation of 5-amino-2,4-di-tert- butylphenol or an acid addition salt thereof
|
JP6494757B2
(ja)
|
2014-11-18 |
2019-04-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
ハイスループット試験高速液体クロマトグラフィーを行うプロセス
|
MA41031A
(fr)
|
2014-11-26 |
2017-10-03 |
Catabasis Pharmaceuticals Inc |
Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
|
WO2016086136A1
(en)
|
2014-11-26 |
2016-06-02 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
|
CA2969587A1
(en)
|
2014-12-05 |
2016-06-09 |
Centre National De La Recherche Scientifique (Cnrs) |
Compounds for treating cystic fibrosis
|
EP3229791A4
(en)
|
2014-12-09 |
2018-09-26 |
Laurus Labs Limited |
Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
|
WO2016094904A1
(en)
|
2014-12-12 |
2016-06-16 |
Celcuity Llc |
Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
|
CA2971850A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
WO2016105484A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
US10344023B2
(en)
|
2014-12-23 |
2019-07-09 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
DK3236983T3
(da)
|
2014-12-24 |
2019-07-15 |
Kither Biotech S R L |
Hidtil ukendt pi3k-gamma-inhibitorpeptid til behandling af sygdomme i åndedrætssystemet
|
JP2018501276A
(ja)
|
2015-01-09 |
2018-01-18 |
ギリアド アポロ, エルエルシー |
非アルコール性脂肪肝疾患の処置のためのacc阻害剤併用療法
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
AU2016217473B2
(en)
|
2015-02-09 |
2021-07-29 |
Sciclone Pharmaceuticals International Ltd. |
Thymosin alpha 1 for use in treatment of cystic fibrosis
|
DE102015002820A1
(de)
|
2015-03-02 |
2016-09-08 |
Marco Schmidt |
Verfahren zur Speicherung genetischer Daten der personalisierten Medizin
|
CN104725314A
(zh)
|
2015-03-23 |
2015-06-24 |
上海皓元化学科技有限公司 |
一种Ivacaftor的新晶型及其制备方法
|
US10196384B2
(en)
|
2015-03-31 |
2019-02-05 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated CFTR modulators
|
GB201507926D0
(en)
|
2015-05-08 |
2015-06-24 |
Proqr Therapeutics N V |
Improved treatments using oligonucleotides
|
US10336703B2
(en)
|
2015-05-12 |
2019-07-02 |
Council Of Scientific And Industrial Research |
Process for the synthesis of ivacaftor and related compounds
|
TWI730959B
(zh)
|
2015-05-19 |
2021-06-21 |
英商葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之雜環醯胺
|
CA3021752A1
(en)
|
2015-06-11 |
2016-12-15 |
Aizant Drug Research Solutions Private Limited |
Nanoparticulate ivacaftor formulations
|
CN105130891B
(zh)
|
2015-08-05 |
2018-03-23 |
上海皓元医药股份有限公司 |
一种Ivacaftor的合成方法及其中间体
|
CN105153105B
(zh)
|
2015-08-15 |
2018-01-19 |
浙江永宁药业股份有限公司 |
1‑(2,2‑二氟苯并[d][1,3]二氧杂环戊烯‑5‑基)环丙烷甲酸的合成方法及其中间体
|
CN105237414B
(zh)
|
2015-09-30 |
2017-03-22 |
浙江永宁药业股份有限公司 |
ivacaftor中间体及其制备方法和用途
|
CN105457038A
(zh)
|
2015-11-09 |
2016-04-06 |
东南大学 |
一种速释型药物磷脂化合物及其药物组合物
|
CN105884628B
(zh)
|
2016-06-06 |
2018-06-29 |
上海工程技术大学 |
2,4-二叔丁基-5-氨基酚的制备方法
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|